Abstract: Methods of farming, domesticating, or cultivating truffle fungi, including isolation and cultivation methods for producing pure truffle fungi, or mini-truffles, typically a Tuber spp. or an Iamai spp. Examples of truffle include Tuber melanosporum, Tuber magnatum, Tuber aestivum, Tuber uncinatum, Tuber borchii, Imaia spp., Tuber macrosporum, Tuber gibbosum, Tuber oregonense, and Tuber lyonii. The isolated pure truffle may then be cultivated on a nutrient substrate, which may be, for example, a fruit, nut, grain, or a portion thereof, resulting in a truffle-flavored food product. Non-limiting examples of such substrates include rye, barley, lentil, wheat, rice, soybeans, pecan, hazelnut, pine nut, English walnut, coffee beans, mustard, cacao, sesame, sunflower, grapes, blackberries, blueberries, cherries, kiwi, mango, raspberries, and huckleberries.

Abstract: Described herein are compositions, methods, kits and devices for the treatment and/or prevention of a wide spectrum of disease conditions. In particular, bacterial populations described herein are live, purified bacteria for the modulation, restoration and/or promotion of the microbiome in the upper respiratory tract of a subject, including the nasal cavity, to promote health. Such bacterial populations may include single or multiple strains for bacteria. The multiple strains of bacteria may be strains from the same or different species, including species of Corynebacterium and/or Dolosigranulum pigrum.

Abstract: Device D for cultivating cell cultures C, wherein said device D has a surface O and comprises on its surface O at least one polymer P wherein said polymer P is a copolymer of at least one monomer M and at least one ester E of (meth)acrylic acid and polyethylene oxide, wherein said monomer M is different from ester E and has at least one ethylenically unsaturated double bond.

Abstract: The disclosure discloses a strain of Lactobacillus crispatus capable of preventing and/or treating Helicobacter pylori infection, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain of Lactobacillus crispatus CCFM1118. The Lactobacillus crispatus CCFM1118 can inhibit Helicobacter pylori, specifically embodied in that: (1) the diameter of an inhibition zone of supernatant of the Lactobacillus crispatus CCFM1118 on Helicobacter pylori can reach 13.14 mm; and (2) the Lactobacillus crispatus CCFM1118 can significantly reduce the adhesion of Helicobacter pylori to AGS cells. Therefore, the Lactobacillus crispatus CCFM1118 has great application prospects in inhibiting Helicobacter pylori (not for the purposes of disease diagnosis and treatment) and preparing Helicobacter pylori inhibitors.

Abstract: Biomanufacturing hygiene control in batch and fed-batch bioreactors is provided using a bioreactor employing a chlorite/Cld system, wherein the bioreactor comprises an engineered cultured cell expressing a recombinant cytoplasmic chlorite dismutase (cCld) sufficient to increase chlorite resistance of the cell, and chlorite sufficient to substantially inhibit growth of one or more contaminating microorganisms in the bioreactor yet not substantially inhibit growth of the cell.

Abstract: A postbiotic preparation for pelvic floor muscle rehabilitation and a preparation method and application thereof. A strain of Lactobacillus plantarum Nice-02 is successfully obtained, and a postbiotic preparation product is successfully developed based on the strain.

Abstract: This invention relates to a method for the direct detection of tick-borne infections, wherein the human/animal body fluid sample, ideally blood sample to be examined is obtained directly on a specified amount of cell technology medium establishing a partially hostile (semi-hostile) environment, the sample and the cell technology medium are mixed, incubated and stored, if required, meanwhile, the cells and pathogens of the subject are in the semi-hostile environment, then corpuscles and pathogens are separated; a small amount of blood cells from the “buffy coat” layer and blood cells located a few cell layers beneath it are supplemented to and mixed with the gained plasma, the sample is concentrated and the test is finally performed to detect pathogens in the plasma and in blood cells. The claimed matter covers cell technology medium applied and its application interesting methods.

Abstract: This invention relates to the use of probiotic yeast cells that produce recombinant parathormone for therapeutic purposes, where probiotic cells that produce rhPTH developed for use in hypoparathyroidism treatment are first microencapsulated, placed into gelatin capsules and then orally administrated.

Abstract: A recombinant bacterium with a high PHA yield and its construction method provide an engineered microorganism that can be used for the production of polyhydroxyalkanoate (PHA). A recombinant Ralstonia eutropha with a high PHA yield includes a promoter for upregulating a phaJ gene and further includes a mutant phaC gene. The recombinant Ralstonia eutropha can be used for producing 3-hydroxybutyrate-co-3-hydroxyhexanoate (PHBHHx) in PHA.

Abstract: The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteroides and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes.

Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

Abstract: The present disclosure provides a simple and secure apparatus and a simple and secure method for selectively detecting a tomato pathogenic fungus. The tomato pathogenic fungus detecting apparatus according to the present disclosure is characterized by including an artificial cell wall, a test sample solution inlet provided above the artificial cell wall, and a culture solution storage part provided under the artificial cell wall, wherein a test sample solution contains a 50 mM to 70 mM buffer solution of a citrate salt in the test sample solution inlet, and the test sample solution has a pH of 5 to 5.5.

Abstract: Provided herein are methods for increasing the yield of an extracellular product synthesized by an organism cultured in a continuous aerobic fermentation system. The extracellular product yield is increased through the use of an organism modified to decreased production of polyhydroxyalkanoate, to increase production of the extracellular product, and to include promoters that can be inducible in response to nutrient limitation conditions. The extracellular product yield is also increased by operating the continuous fermentation system under particular nutrient limitation conditions. Also provided are non-naturally occurring organisms that have been modified for use with the provided methods, and extracellular products made using the provided methods.

Abstract: Provided are means, methods, and compositions effective for obesity treatment using probiotics such as bifidobacteria or lactobacilli. Also, a method of selecting probiotic bacteria having a body fat reducing effect, and a method of selecting responders to probiotic bacteria having an anti-obesity action are provided. Provided is a composition for reducing body fat, or the like, which contains Bifidobacterium and/or lactobacilli as an active ingredient, and is used for a pre-obesity group or an obesity disease including intestinal flora in which the ratio of the phylum Firmicutes to the phylum Bacteroidetes has a high value.

Abstract: Methods for promoting intestinal health of a subject in need thereof and for enhancing antioxidation in a subject in a subject in need thereof are provided. The methods include administering to the subject a prebiotic composition, which includes grape ferment, lactitol, and fructooligosaccharide. The weight ratio of the grape ferment, the lactitol, and the fructooligosaccharide falls within the range of 1-2:1-2:1-2. The grape ferment is obtained by fermenting grape extract with Saccharomyces cerevisiae and Streptococcus thermophilus.

Abstract: The invention relates to the pharmaceutical or non-pharmaceutical use of an effective amount of spirulina and/or of an extract/extracts of spirulina for improving the bioavailability of orally administered curcumin in humans or animals. The invention also includes pharmaceutical or non-pharmaceutical preparations including spirulina and/or extracts of spirulina containing curcumin having improved bioavailability.

Abstract: Provided is a method for improving the yield of rhamnolipids comprising culturing in medium containing a triglyceride containing oil and sweetener as a carbon source.

Abstract: Embodiments of the invention relate generally to processes for the production and processing of polyhydroxyalkanoates (PHA) from carbon sources. In several embodiments, PHAs are produced at high efficiencies from carbon-containing gases through the utilization of a regenerative polymerization system.

Abstract: The present invention relates to an additive to poultry feed including nitrates, nitrites or their mixtures that reduces the incidence of pectoral myopathy in poultry, for example, wooden breast myopathy in broiler chickens. In one aspect, a method for reducing the incidence of pectoral myopathy in poultry is disclosed. The method includes feeding poultry a feed having one or more nitrates, one or more nitrites, or a mixture thereof, wherein the amount of nitrates and/or nitrites in the feed is 3 g to 2,500 g per ton of feed.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one Corynebacterium sp, Staphylococcus pasteuri and, optionally, Staphyloccocus epidermidis for use as a medicament, in particular for use in the prevention or treatment of S. aureus colonization.